Explore-OSA
57 evidence topics · 10 sources
Objective
Purpose stated in the ClinicalTrials.gov record
Objective stated in the congress abstract
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual)” (opens the source at this quote in a new tab)
“2025-02-28” (opens the source at this quote in a new tab)
“Primary Completion (Actual)” (opens the source at this quote in a new tab)
“2025-12-17” (opens the source at this quote in a new tab)
“Study Completion (Actual)” (opens the source at this quote in a new tab)
Registered locations
Planned number of sites at trial initiation
Other study identifiers
Results reporting status in the ClinicalTrials.gov record
Study design
Randomized, double-blind, placebo-controlled crossover design in the congress abstract
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “48” |
Exploratory two-period, two-sequence design described by the sponsor
Eligibility criteria
Key eligibility criteria in the congress abstract
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Ages eligible in the ClinicalTrials.gov record
Treatment
Lorundrostat 50 mg or placebo once daily in the evening
Treatment sequences in the congress abstract
Interventions and positive airway pressure use in the ClinicalTrials.gov record
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Sponsor rationale for an effect on upper airway obstruction
Investigator rationale for aldosterone synthase inhibition in obstructive sleep apnea
Apnea-hypopnea index as the most studied measure of sleep apnea severity
“OSA has well established cardiovascular and neurocognitive sequelae, although the optimal metric to assess its severity and/or potential response to therapy remains unclear.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The apnea-hypopnea index (AHI) is well established; thus, we review its history and predictive value in various different clinical contexts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the AHI is often criticized for its limitations, it remains the best studied metric of OSA severity, albeit imperfect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Apnea-hypopnea index as the primary endpoint of the trials supporting an approved obstructive sleep apnea indication
Apnea-hypopnea index as a phase 3 primary endpoint
“The primary end point was the change in the apnea–hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The AHI was measured by laboratory polysomnography at screening, week 20, and week 52.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint: office systolic blood pressure
Key secondary objective stated at trial initiation
Registered secondary outcome measures
Rationale for blood pressure endpoints in obstructive sleep apnea
Systolic blood pressure reduction and major cardiovascular events
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment at trial initiation
Enrollment in the ClinicalTrials.gov record
Participants reported in the topline release
Participants reported in the congress abstract
Description of analysis sets
Parallel-arm and crossover analyses
Results
Participant disposition
No evidence found.
Baseline characteristics
Body mass index, apnea-hypopnea index, and systolic blood pressure at baseline
Efficacy results
Summary: systolic blood pressure figures in the congress abstract and the company releases
The congress abstract reports the preplanned parallel-arm analysis of the first treatment period as a placebo-adjusted reduction in systolic blood pressure of 10.1 mmHg (P=0.0089). The NDA acceptance release and the AHA Hypertension 2026 release report within-group reductions of 11.1 mmHg with lorundrostat (p<0.0001) and 1.0 mmHg with placebo (p=NS) at week 4, and the NDA acceptance release attributes these figures to the pre-planned parallel arm analysis of the first period; the difference between the two within-group figures is 10.1 mmHg. The abstract and the NDA acceptance release both report a placebo-adjusted reduction of 6.2 mmHg (P<0.0003) in the crossover analysis of both treatment periods. The NDA acceptance release reports topline results.
Primary endpoint: apnea-hypopnea index not met
Office systolic blood pressure: placebo-adjusted estimates in the congress abstract
Office systolic blood pressure: within-group changes and crossover estimate in the topline release
Nighttime blood pressure
No evidence found.
Health-related quality of life and patient-reported outcomes
Functional Outcomes of Sleep Questionnaire-10
Epworth Sleepiness Scale and PROMIS sleep measures
No evidence found.
Safety results
Serious adverse events and tolerability in the congress abstract
Study limitations
Summary
Explore-OSA was a phase 2 crossover trial with two 4-week treatment periods separated by a 2-week washout; the registry lists 48 enrolled participants and the congress abstract describes 47. The primary endpoint, the placebo-adjusted change in apnea-hypopnea index at week 4, showed “no difference in AHI response between lorundrostat- and placebo-treated participants”. Office systolic blood pressure was a secondary endpoint, and the public results come from a congress abstract and company releases; no peer-reviewed publication or posted registry results were located, and the registry record shows a certification/extension submission dated 2026-08-17. The registry lists nighttime average systolic blood pressure as the first secondary outcome measure and also lists the Epworth Sleepiness Scale and two PROMIS sleep measures; no result for any of these was located in the public documents. The parallel-arm systolic blood pressure estimate uses the first treatment period alone, and the abstract and the company releases state it differently. The abstract states that “more than a third of participants were using PAP therapy”. Public safety reporting is limited to the absence of serious adverse events and of serum potassium values above 5.5 mmol/L. Eligibility excluded participants with eGFR below 45 mL/min/1.73 m2 and participants taking a GLP-1 agonist, and the registry lists 27 locations.